

Alan Breier  
10/09/00 05:28 PM

To: Robert W Baker/AM/LLY@Lilly  
cc: Charles M Beasley Jr/AM/LLY@Lilly, Christopher C  
Bomba/AM/LLY@LILLY, Patrizia Cavazzoni/AM/LLY@Lilly, Suni  
Keeling/AM/LLY@LILLY  
Subject: Re: meeting with endocrinologic consultants

Robert,

I appreciate your comments. I think we need to proceed with the suggested analyses post haste.

Alan  
Robert W Baker

**Robert W Baker**



10/09/2000 03:42 PM

To: Charles M Beasley Jr/AM/LLY@Lilly, Alan Breier/AM/LLY@Lilly  
cc: Christopher C Bomba/AM/LLY@LILLY, Patrizia Cavazzoni/AM/LLY@Lilly, Suni Keeling/AM/LLY@LILLY

Subject: Re: meeting with endocrinologic consultants

FYI. My take was that this board of academic endocrinologists was impressed enough by magnitude of weight gain and number of reports in the spontaneous adverse event database that they were predisposed toward skepticism to any analysis that did not find higher hyperglycemia rates on olanzapine than comparators.

Charles - do you think it appropriate to look at secondary analysis that does not exclude baseline abnormal and another looking at mean changes in glucose?

Alan - I believe that what Tom is referring to as "not the way Lilly typically does business" are suggestions to more vocally assert that olanzapine may have a problem on the glucose issue and, rather than moving forward with our analyses, turning all info over to an independent board for review, conclusions, and dissemination. Neither strikes me as the appropriate step, but this alarmed the Lilly attendees when linked to the Rezulon comparison. Charles did let them know that already we have sent several volumes with all our info to FDA, but I'm not sure that they fully appreciated this.

Thanks,

R

----- Forwarded by Robert W Baker/AM/LLY on 10/09/2000 03:29 PM -----



Thomas M Brodie  
10/09/2000 03:10 PM

To: Robert W Baker/AM/LLY@Lilly  
cc: Eugene R Thiem/AM/LLY@LILLY

Subject: Re: meeting with endocrinologic consultants

Robert.....clearly, this group of Endocrinologists (who spoke up and I would rate those who did speak up as the leaders of the pack) are very concerned with the approach Lilly is taking towards the issue that Zyprexa leads to diabetes. I can only hope that you and all of the team who attended the NADAB meeting are gaining the ear of senior leadership and articulating this finding. Although the boards recommendation is probably not the way Lilly typically does business, I do believe they made a very strong point that unless we come clean on this, it could get much more serious than we might anticipate.

ZY 2051 406

need additional time at future meetings (next one is Feb. 2001) please let me know. It was great meeting you as well.

Regards,  
Tom

ZY 2051 407